Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.63 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.58 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.54 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | TNKS | O95271 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | PARP1 | P09874 | 3/20 | 0.51 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.51 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29802950 | 1.00 | PPARG (0.63) | PPARGCYP11B1CYP11B2KDM4EUSP2 | |
| SCHEMBL19925815 | 0.86 | PPARG (0.69) | PPARGCYP11B1CYP11B2KDM4EUSP2 | |
| SCHEMBL5695477 | 0.81 | PPARG (0.63) | PPARGCYP11B1CYP11B2KDM4EUSP2 | |
| SCHEMBL9471231 | 0.81 | PPARG (0.63) | PPARGCYP11B1CYP11B2KDM4EUSP2 | |
| SCHEMBL29803387 | 0.81 | PPARG (0.63) | PPARGCYP11B1CYP11B2KDM4EUSP2 | |
| SCHEMBL9972758 | 0.81 | PPARG (0.63) | PPARGCYP11B1CYP11B2KDM4EUSP2 | |
| SCHEMBL3814678 | 0.81 | PPARG (0.63) | PPARGCYP11B1CYP11B2KDM4EUSP2 | |
| SCHEMBL30876965 | 0.81 | PPARG (0.63) | PPARGCYP11B1CYP11B2KDM4EUSP2 | |
| SCHEMBL3399447 | 0.81 | PPARG (0.63) | PPARGCYP11B1CYP11B2KDM4EUSP2 | |
| SCHEMBL11637530 | 0.81 | PPARG (0.63) | PPARGCYP11B1CYP11B2KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4090654-B1 | METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS | LUPIN LTD (IN) | 2025-07-09 | — | — | EP | claimed |
| US-12344592-B2 | Methods, processes and intermediates for preparing chroman compounds | LUPIN LIMITED (IN) | 2025-07-01 | — | — | US | claimed |
| CN-114981253-B | Process and intermediates for preparing chroman compounds and methods therefor | 印度鲁宾有限公司 | 2024-06-18 | — | — | CN | claimed |
| US-20230140054-A1 | METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS | LUPIN LIMITED (IN) | 2023-05-04 | — | — | US | claimed |
| EP-4090654-A1 | METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS | Lupin Limited (IN) | 2022-11-23 | — | — | EP | claimed |
| CN-114981253-A | Process and intermediates for preparing chroman compounds and methods therefor | 印度鲁宾有限公司 | 2022-08-30 | — | — | CN | claimed |
| WO-2021144814-A1 | METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS | LUPIN LIMITED (IN) | 2021-07-22 | — | — | WO | claimed |
| US-12390444-B2 | Stabilizing vitamin C topical formulations | MF BEAUTY PARTNERS LLC (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250228756-A1 | Anhydrous Urea Emulsions with a Retinoid Agent | MF BEAUTY PARTNERS LLC | 2025-07-17 | — | — | US | disclosed |
| EP-4090654-B1 | METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS | LUPIN LTD (IN) | 2025-07-09 | — | — | EP | disclosed |
| US-12344592-B2 | Methods, processes and intermediates for preparing chroman compounds | LUPIN LIMITED (IN) | 2025-07-01 | — | — | US | disclosed |
| US-20250114288-A1 | HIGH-POTENCY VITAMIN C AND SUGAR ALCOHOL TOPICAL FORMULATIONS | MF BEAUTY PARTNERS LLC | 2025-04-10 | — | — | US | disclosed |
| US-20240390238-A1 | MINIMALIST EMULSION COMPOSITIONS | ICB (an ABC), LLC | 2024-11-28 | — | — | US | disclosed |
| US-8349850-B2 | Heterocyclic compounds and uses thereof in the treatment of sexual disorders | ATIR HOLDING S.A. (LU) | 2013-01-08 | — | — | US | disclosed |
| EP-2233472-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | Atir Holding S.A. (LU) | 2010-09-29 | — | — | EP | disclosed |
| US-20100029671-A1 | Heterocyclic Compounds And Uses Thereof In The Treatment Of Sexual Disorders | ATIR HOLDING S.A. (LU) | 2010-02-04 | — | — | US | disclosed |
| EP-2010505-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | Atir Holding S.A. (LU) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007110868-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF IN THE TREATMENT OF SEXUAL DISORDERS | ATIR HOLDING S.A. (LU) | 2007-10-04 | — | — | WO | disclosed |
| US-4179447-A | ANTIALLERGENS | WARNER-LAMBERT COMPANY (US) | 1979-12-18 | — | — | US | disclosed |
| US-4158663-A | FROM 4-METHOXYCOUMARINS USING SODIUM HYDRIDE AND DIMETHYLSULFOXIDE | WARNER-LAMBERT COMPANY (US) | 1979-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029671-A1 | Heterocyclic Compounds And Uses Thereof In The Treatment Of Sexual Disorders | PDE5A, PDE3B, PDE3A | PPARG 722/4885CYP11B1 112/4885CYP11B2 100/4885 |
| US-20230140054-A1 | METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS | CASR, CALCR, RYR1 | PPARG 824/4885CYP11B1 571/4885CYP11B2 686/4885 |
| US-20250114288-A1 | HIGH-POTENCY VITAMIN C AND SUGAR ALCOHOL TOPICAL FORMULATIONS | PROC, ADH1C, GALC | PPARG 1877/4885CYP11B1 3811/4885CYP11B2 3922/4885 |
| US-20240390238-A1 | MINIMALIST EMULSION COMPOSITIONS | ADH7, PROC, OTC | PPARG 546/4885CYP11B1 3426/4885CYP11B2 3240/4885 |
| US-12390444-B2 | Stabilizing vitamin C topical formulations | PROC, CUTA, NISCH | PPARG 1829/4885CYP11B1 4051/4885CYP11B2 4195/4885 |
| US-12344592-B2 | Methods, processes and intermediates for preparing chroman compounds | CASR, CALCR, RYR1 | PPARG 824/4885CYP11B1 571/4885CYP11B2 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.